Key Takeaways
- • Multiple private equity firms—Archimed, Grovecourt, and Kain Capital—are actively pursuing radiology platform deals, signaling sustained institutional appetite for healthcare imaging consolidation.
- • Latticework Capital and Edgehill Partners are backing Life Science Connect's acquisition of CDMO (contract development and manufacturing organization) brands, expanding the platform's manufacturing and outsourcing capabilities through add-on M&A.
- • The dual focus on radiology platforms and CDMO add-ons reflects broader PE strategy to build scaled, diversified healthcare services businesses through both primary acquisitions and bolt-on deals.
- • CDMO sector consolidation continues to attract sponsor capital as life sciences companies seek outsourced manufacturing partners with expanded capabilities and geographic reach.
Summary
Private equity sponsors are demonstrating sustained momentum across healthcare services, with multiple firms actively competing for radiology platform assets while simultaneously backing manufacturing-focused add-on acquisitions. Archimed, Grovecourt, and Kain Capital have emerged as principal buyers in the radiology marketplace, each pursuing platform or bolt-on opportunities within diagnostic imaging networks. This competitive deal flow underscores persistent institutional conviction that radiology—characterized by recurring revenue, defensive demand, and operational leverage potential—remains an attractive consolidation target.
Parallel to radiology activity, Latticework Capital and Edgehill Partners are executing a complementary strategy by backing Life Science Connect's acquisition of CDMO brands. This move expands Life Science Connect's platform into contract development and manufacturing, sectors experiencing significant sponsor-backed consolidation as biotechnology and pharmaceutical companies increasingly outsource manufacturing operations. The CDMO add-on acquisitions represent value-creation plays typical of mid-market PE strategy: acquiring smaller, specialized manufacturing capabilities and integrating them into a larger platform to achieve scale, operational efficiencies, and cross-selling opportunities.
The convergence of radiology deals and CDMO consolidation illustrates institutional investors' focus on building multi-service healthcare businesses capable of serving diverse end-market segments. While radiology platforms benefit from imaging procedure volume and bundled service expansion, CDMO platforms capitalize on rising outsourcing demand from biotech sponsors. Both sectors offer sponsor-friendly characteristics: predictable cash flows, limited commodity exposure, and management teams amenable to operational and financial engineering under PE ownership.
These transactions reflect a broader healthcare services consolidation trend where sponsors continue to deploy capital into fragmented, relationship-driven markets offering margin expansion and revenue synergy opportunities. The involvement of established sponsors like Archimed and Edgehill indicates that despite macroeconomic headwinds and elevated interest rates, institutional capital remains allocated to healthcare infrastructure plays viewed as essential, recurring-revenue businesses with durable competitive moats.
Parallel to radiology activity, Latticework Capital and Edgehill Partners are executing a complementary strategy by backing Life Science Connect's acquisition of CDMO brands. This move expands Life Science Connect's platform into contract development and manufacturing, sectors experiencing significant sponsor-backed consolidation as biotechnology and pharmaceutical companies increasingly outsource manufacturing operations. The CDMO add-on acquisitions represent value-creation plays typical of mid-market PE strategy: acquiring smaller, specialized manufacturing capabilities and integrating them into a larger platform to achieve scale, operational efficiencies, and cross-selling opportunities.
The convergence of radiology deals and CDMO consolidation illustrates institutional investors' focus on building multi-service healthcare businesses capable of serving diverse end-market segments. While radiology platforms benefit from imaging procedure volume and bundled service expansion, CDMO platforms capitalize on rising outsourcing demand from biotech sponsors. Both sectors offer sponsor-friendly characteristics: predictable cash flows, limited commodity exposure, and management teams amenable to operational and financial engineering under PE ownership.
These transactions reflect a broader healthcare services consolidation trend where sponsors continue to deploy capital into fragmented, relationship-driven markets offering margin expansion and revenue synergy opportunities. The involvement of established sponsors like Archimed and Edgehill indicates that despite macroeconomic headwinds and elevated interest rates, institutional capital remains allocated to healthcare infrastructure plays viewed as essential, recurring-revenue businesses with durable competitive moats.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.